Abbott Laboratories (ABT) is Drawing Interest from Investors: Key Information You Need to Know

Abbott Laboratories: Recent Trends and Outlook

Abbott Laboratories (ABT) has recently become a focal point for investors, drawing considerable attention on Zacks.com. If you're considering this stock, it's important to review the key factors that could influence its near-term performance.

Over the past month, Abbott, known for its infant nutrition products, medical devices, and pharmaceuticals, has seen its share price rise by 4.2%. In contrast, the Zacks S&P 500 composite index declined by 1.3%, and the Zacks Medical - Products sector, which includes Abbott, fell by 1.8%. This raises the question: what lies ahead for Abbott's stock?

While news headlines and speculation can cause short-term price swings, long-term investment decisions are ultimately driven by fundamental factors.

Focus on Earnings Forecasts

At Zacks, the primary focus is on changes in earnings forecasts, as these are considered the most reliable indicators of a stock's intrinsic value. The present value of a company's anticipated future earnings is a key determinant of its fair market price.

We monitor how analysts adjust their earnings projections in response to business developments. When these estimates are revised upward, it often signals a higher fair value, which can attract buyers and push the stock price higher. Research consistently shows a strong link between earnings estimate revisions and short-term stock price movements.

• For the current quarter, Abbott is projected to earn $1.15 per share, a 5.5% increase from the same period last year. This estimate has not changed in the past month.
• For the full fiscal year, the consensus estimate is $5.68 per share, up 10.3% year-over-year, with no recent changes.
• Looking ahead to the next fiscal year, analysts expect earnings of $6.23 per share, representing a 9.8% increase, and this estimate has also remained steady over the past 30 days.

The Zacks Rank, a proprietary rating system with a proven track record, leverages these earnings estimate trends to provide a clearer picture of a stock's likely direction. Currently, Abbott holds a Zacks Rank #3 (Hold), reflecting the recent stability in consensus estimates and other related factors.

Trends in 12-Month EPS Estimates

The chart above illustrates how analysts' forward 12-month earnings per share estimates for Abbott have evolved over time.

Revenue Growth Projections

While earnings growth is a strong indicator of financial health, sustained revenue growth is essential for long-term profitability. Understanding a company's sales outlook is therefore crucial.

• For the current quarter, Abbott's sales are expected to reach $11.03 billion, a 6.5% increase from the previous year.
• For the current fiscal year, projected revenue is $47.74 billion, up 7.7% year-over-year.
• For the following fiscal year, sales are forecasted at $51.13 billion, a 7.1% increase.

Recent Financial Results and Surprises

In its most recent quarter, Abbott reported revenue of $11.46 billion, marking a 4.4% year-over-year rise. Earnings per share came in at $1.50, compared to $1.34 in the same quarter last year.

However, these revenues were 2.76% below the Zacks Consensus Estimate of $11.78 billion, while earnings matched expectations. Over the last four quarters, Abbott has exceeded consensus EPS estimates twice and surpassed revenue estimates once.

Valuation Insights

Evaluating a stock's valuation is essential for making informed investment choices. Comparing current valuation ratios—such as price-to-earnings, price-to-sales, and price-to-cash flow—against historical averages and industry peers helps determine whether a stock is fairly priced, overvalued, or undervalued.

The Zacks Value Style Score, which assesses both conventional and alternative valuation metrics, ranks stocks from A (best) to F (worst). Abbott currently receives a grade of C, suggesting its valuation is in line with industry peers.

Summary

The information presented here, along with additional resources on Zacks.com, can help you decide whether Abbott deserves your attention. Its current Zacks Rank #3 indicates that the stock is likely to perform similarly to the broader market in the near future.